Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 7/20 | 0.48 |
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | BTK | Q06187 | 7/20 | 0.40 |
| ▸ | LCK | P06239 | 2/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | CDK14 | O94921 | 2/20 | 0.38 |
| ▸ | CCNY | Q8ND76 | 2/20 | 0.38 |
| ▸ | CCNK | O75909 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410261 | 1.00 | JAK3 (0.48) | JAK3EGFRBTKLCKCDK4 | |
| SCHEMBL17928309 | 1.00 | JAK3 (0.48) | JAK3EGFRBTKLCKCDK4 | |
| SCHEMBL26469442 | 0.96 | JAK3 (0.45) | JAK3EGFRBTKLCKCDK4 | |
| SCHEMBL20892949 | 0.93 | JAK3 (0.41) | JAK3EGFRBTKLCKCDK4 | |
| SCHEMBL20892752 | 0.93 | JAK3 (0.41) | JAK3EGFRBTKLCKCDK4 | |
| SCHEMBL21884776 | 0.88 | JAK3 (0.46) | JAK3EGFRBTKLCKCDK4 | |
| SCHEMBL409255 | 0.86 | BTK (0.41) | JAK3EGFRBTKLCKCDK4 | |
| SCHEMBL20892791 | 0.86 | JAK3 (0.36) | JAK3EGFRBTKCDK4CDK7 | |
| SCHEMBL410131 | 0.84 | CCR2 (0.39) | JAK3EGFRBTKLCKCDK4 | |
| SCHEMBL19999892 | 0.83 | JAK3 (0.42) | JAK3EGFRBTKLCKCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200289515-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20190276426-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | CORVUS BIOPHARMACEUTICALS, LTD. (KY) | 2019-04-11 | — | — | US | disclosed |
| US-20180085372-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2017-12-21 | — | — | US | disclosed |
| US-8748438-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748439-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8741908-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8735404-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735403-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8658653-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130005745-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC (US) | 2013-01-03 | — | — | US | disclosed |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8158786-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110257203-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Phamarcyclics, Inc. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | JAK3 253/4885EGFR 697/4885BTK 2/4885 |
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | JAK3 110/4885EGFR 711/4885BTK 2/4885 |
| US-20110257203-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | JAK3 72/4885EGFR 836/4885BTK 1/4885 |
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | JAK3 192/4885EGFR 1028/4885BTK 329/4885 |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | JAK3 98/4885EGFR 357/4885BTK 1/4885 |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | IRAK1, IRAK4, IRAK2 | JAK3 192/4885EGFR 1028/4885BTK 329/4885 |
| US-20180085372-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | JAK3 72/4885EGFR 836/4885BTK 1/4885 |
| US-20190276426-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | JAK3 192/4885EGFR 1028/4885BTK 329/4885 |
| US-20200289515-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | JAK3 45/4885EGFR 497/4885BTK 1/4885 |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | JAK3 253/4885EGFR 697/4885BTK 2/4885 |
| US-20130005745-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | JAK3 72/4885EGFR 836/4885BTK 1/4885 |
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | ABL1, BTK, LYN | JAK3 110/4885EGFR 711/4885BTK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.